Harrow (HROW) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Harrow (HROW) over the past year, gaining 113.4% versus a loss of 26.9%. Harrow is the larger company by market cap ($1.15 billion vs $1.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | LBRX |
|---|---|---|
| Share price | $30.62 | $34.16 |
| Market cap | $1.15B | $1.10B |
| 1-day change | +0.89% | -0.29% |
| YTD return | -37.51% | +53.46% |
| 1-year return | -26.92% | +113.37% |
| 5-year return | +209.61% | — |
| P/E ratio (TTM) | — | 341.60 |
| Forward P/E | 11.04 | — |
| EPS (TTM) | $-0.99 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $50.16 |
| 52-week low | $28.54 | $14.32 |
| Distance from 52-week high | -44.18% | -31.90% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +112.28% | +67.74% |
| Average volume | 555.14K | 341.17K |
| Shares outstanding | 37.49M | 32.26M |
| Employees | 373 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed HROW by 140.3 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
HROW vs LBRX FAQ
Which is bigger, Harrow or LB Pharmaceuticals?
Harrow (HROW) is larger, with a market capitalization of $1.15B compared with $1.10B for LB Pharmaceuticals (LBRX).
Which stock has performed better over the past year, HROW or LBRX?
LBRX returned +113.37% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.